Dermatology

Dermatologists introduce this series providing and overview of seborrheic dermatitis (SD), highlighting common causes, contributing factors, and the various ways it may present in different patient populations.

In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.

In this interview, Dr. Chovatiya responds to questions about the new FDA approval of secukinumab for patients with hidradenitis suppurativa.

Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.

This segment of Dr. Kwatra’s latest interview featured a discussion on the future of prurigo nodularis treatment and the implications of his team’s research.

In this interview, Dr. Kwatra explored the recent phase 3 data from the Olympia 2 study on nemolizumab treatment for patients with prurigo nodularis.

In this Fall Clinical Dermatology Conference interview, Dr. Burgess answered several questions related to aesthetic treatments for patients with skin of color, including specific recommendations.

In his ‘Early Dermatology Practice Pearls’ presentation, Dr. Song described tips for dermatologists. In this interview segment, he continues this discussion.

In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

In this interview segment, Dr. Song provided several unique viewpoints presented in his conference talk ‘Early Dermatology Practice Pearls.’

Dr. Eichenfield used this interview segment to respond to the FDA’s recent decision not to approve dupilumab for chronic spontaneous urticaria.

Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.

In this interview segment, Dr. Nestor speaks on some of his biggest takeaways from his talk ‘What’s Coming Up Next?’ given at the Fall Clinical Dermatology conference.

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

This interview featured a discussion with Dr. Bhatia on the future of actinic keratosis diagnosis and treatment, as well as advances and important facts for clinicians to remember about risk.

These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.

This interview at the Fall Clinical Dermatology conference featured a discussion with Dr. Bhatia regarding key insights from his talk ‘What You Need To Know NOW About Actinic Keratosis.’

Susan C. Taylor, MD, emphasizes the importance of understanding the unique biological differences and needs of individuals with skin of color.

This presentation at the Fall Clinical Dermatology conference in Las Vegas explored the topic of advancements in HS treatment.

In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

This segment of Dr. Okoye’s interview featured a set of examples of HS patients’ struggles with access to medication, as well as discussion of potential solutions.

This interview with Dr. Okoye featured a discussion about her presentation at the SHSA conference, specifically regarding healthcare disparities for HS patients.

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.